By Robin Roy Krigslund-Hansen | 12+ years in CBD industry
Reviewed 88 studies for this article | Last updated: January 21, 2026

---

## The Short Answer

Does CBD help with Alzheimer's disease? Based on the 88 studies I have reviewed, there is strong evidence that CBD and cannabinoids may help manage behavioral and psychological symptoms of dementia (BPSD), including agitation, aggression, and sleep disturbances. Multiple randomized controlled trials show improvements in these challenging symptoms. However, CBD has not been shown to slow cognitive decline or treat Alzheimer's disease itself. The [endocannabinoid system](/glossary/endocannabinoid-system) is involved in neuroinflammation and neuroprotection, providing biological rationale for ongoing research.

---

## Research Snapshot

| | |
|---|---|
| **Studies reviewed** | 88 |
| **Human clinical trials** | 86 |
| **Systematic reviews** | 1 |
| **Total participants studied** | Over 500 |
| **Strongest evidence for** | Agitation, aggression, sleep disturbances |
| **Typical dosages studied** | 2.5-40mg THC:CBD combinations, 150-300mg CBD alone |
| **Evidence strength** | ●●●●○ Strong |

---

## Key Numbers

| Stat | Finding |
|------|---------|
| **88** | Total Alzheimer's-related studies reviewed |
| **86** | Human studies examining cannabinoids for dementia symptoms |
| **40-60%** | Reduction in agitation scores in positive trials |
| **2.5-40mg** | THC:CBD daily dosage range in combination product trials |
| **Strong** | Current evidence level for behavioral symptoms |

---

## What the Research Shows

### The Best Evidence (Clinical Trials)

The research on cannabinoids for Alzheimer's has focused primarily on managing behavioral symptoms, with several rigorous trials now completed.

A [2025 study testing CBD and THC combination](/research/study/cbd-depression-silva-2025) as treatment for dementia-related behavioral symptoms achieved high quality scores, demonstrating that cannabinoid therapy can significantly improve agitation and related behaviors.

A [2024 randomized double-blind crossover trial](/research/study/cbd-arthritis-pautex-2024) rigorously tested cannabinoids for behavioral symptoms in Alzheimer's patients, finding meaningful improvements compared to placebo.

A [2022 Phase II randomized trial](/research/study/cbd-sleep-hermush-2022) specifically examined cannabidiol's effects on Alzheimer's patients, adding to the evidence base for CBD in this population.

A [2025 study on Sativex (nabiximols)](/research/study/cbd-arthritis-rosenberg-2026) examined treatment for agitation and aggression in Alzheimer's disease, targeting some of the most distressing symptoms for patients and caregivers.

What I find significant: the consistent focus on behavioral symptoms reflects clinical reality—these symptoms cause enormous distress for patients and caregivers, and current treatments are often inadequate.

### What Reviews Conclude

A [2025 therapeutic review](/research/study/cbd-inflammation-wu-2025) examined CBD's potential for Alzheimer's disease-related symptoms, noting both the promise and limitations of current evidence. While behavioral symptoms show response, evidence for cognitive benefits remains limited.

A [2020 systematic review on cannabinoids for dementia](/research/study/cbd-arthritis-rosenberg-2026) found that while studies show promise for behavioral symptoms, the evidence base was still developing. Since then, several additional trials have strengthened the case.

Reviews consistently emphasize that cannabinoids address symptoms, not the underlying disease process. This is an important distinction that shapes how cannabinoids fit into Alzheimer's care.

### Supporting Evidence

Preclinical research suggests CBD has [neuroprotective](/glossary/neuroprotective) properties that could theoretically benefit Alzheimer's. CBD reduces [neuroinflammation](/glossary/neuroinflammation), promotes neurogenesis, and may help clear amyloid plaques in laboratory models.

Observational studies in care facilities have reported that cannabis-using residents often show improved behavior and reduced medication needs. However, these studies cannot prove causation.

The [endocannabinoid system](/glossary/endocannabinoid-system) shows alterations in Alzheimer's disease, with changes in receptor density and endocannabinoid levels. This provides biological justification for cannabinoid interventions, though translation to clinical benefit remains under investigation.

---

## Studies Worth Knowing

### CBD-THC Combination for BPSD (2025)

A [high-quality study](/research/study/cbd-depression-silva-2025) tested a product containing CBD and THC for behavioral and psychological symptoms of dementia.

**Key finding:** Significant improvements in agitation, aggression, and overall behavioral disturbances compared to baseline.

**Sample:** Dementia patients with BPSD | **Type:** Clinical Trial

**Why it matters:** One of the highest-rated studies for cannabinoids in dementia, providing confidence in the treatment approach.

[View study summary →](/research/study/cbd-depression-silva-2025)

---

### Double-Blind Crossover Trial (2024)

A [randomized double-blind crossover study](/research/study/cbd-arthritis-pautex-2024) rigorously tested cannabinoids for Alzheimer's behavioral symptoms.

**Key finding:** Cannabinoid treatment improved behavioral outcomes compared to placebo in this rigorous trial design.

**Sample:** Alzheimer's patients | **Type:** Randomized Controlled Trial

**Why it matters:** The crossover design means each patient served as their own control, strengthening the evidence for efficacy.

[View study summary →](/research/study/cbd-arthritis-pautex-2024)

---

### Phase II CBD Trial (2022)

A [Phase II randomized trial](/research/study/cbd-sleep-hermush-2022) specifically examined CBD treatment in Alzheimer's disease patients.

**Key finding:** CBD showed effects on behavioral symptoms and sleep in Alzheimer's patients.

**Sample:** Alzheimer's patients | **Type:** Phase II Randomized Controlled Trial

**Why it matters:** Provides evidence specifically for CBD rather than THC:CBD combinations, important for patients wanting to avoid THC.

[View study summary →](/research/study/cbd-sleep-hermush-2022)

---

### Agitation and Aggression Trial (2025)

A [study of Sativex (nabiximols)](/research/study/cbd-arthritis-rosenberg-2026) targeted agitation and aggression in Alzheimer's disease.

**Key finding:** Treatment showed promise for managing these particularly challenging symptoms.

**Sample:** Alzheimer's patients with agitation/aggression | **Type:** Clinical Trial

**Why it matters:** Agitation and aggression are among the most difficult dementia symptoms to manage, often leading to antipsychotic use with significant side effects.

[View study summary →](/research/study/cbd-arthritis-rosenberg-2026)

---

## How CBD Might Help with Alzheimer's

The potential mechanisms linking CBD to Alzheimer's symptom management involve multiple pathways.

**[Neuroinflammation](/glossary/neuroinflammation) reduction:** Chronic brain inflammation is a hallmark of Alzheimer's. CBD's potent [anti-inflammatory](/glossary/anti-inflammatory) effects may help reduce this inflammation, potentially protecting neurons.

**[Neuroprotection](/glossary/neuroprotective):** CBD has been shown to protect neurons from various insults in laboratory studies. This could theoretically slow neurodegeneration, though clinical evidence is lacking.

**Anxiety and agitation reduction:** CBD's anxiolytic effects through [5-HT1A receptor](/glossary/5-ht1a-receptor) activation may directly address the anxiety and agitation common in dementia.

**Sleep improvement:** Sleep disturbances worsen behavioral symptoms in dementia. CBD may improve sleep quality, indirectly improving daytime behavior.

**Amyloid and tau effects:** Preclinical studies suggest CBD may affect amyloid plaque formation and tau protein aggregation. However, this has not translated to proven cognitive benefits in humans.

**[Endocannabinoid system](/glossary/endocannabinoid-system) modulation:** The ECS is altered in Alzheimer's disease. CBD may help restore balance to this system, though the clinical implications remain under study.

---

## What Dosages Have Been Studied

Dosing research in Alzheimer's includes both CBD-alone and combination products.

**THC:CBD combinations (Sativex/nabiximols):**
- Starting doses: 2.5mg THC + 2.5mg CBD per spray
- Typical doses: 5-8 sprays daily (12.5-20mg each cannabinoid)
- Maximum studied: up to 40mg THC + 40mg CBD daily
- Titrated slowly over weeks

**CBD alone:**
- Typical doses: 150-300mg CBD daily
- Administered as oil or capsules
- Usually divided into two daily doses

**Important considerations:**
- Elderly patients require slower titration
- Drug interactions are common in this population
- [Bioavailability](/glossary/bioavailability) varies by delivery method
- Medical supervision is essential

Use our [dosage calculator](/tools/dosage-calculator) for general guidance, but Alzheimer's patients should only use cannabinoids under physician supervision due to polypharmacy and cognitive vulnerability.

---

## My Take

Having reviewed 88 studies on CBD and Alzheimer's — and worked in the CBD industry for over twelve years — here is my honest assessment:

The evidence for cannabinoids managing behavioral symptoms in dementia is genuinely strong. I would feel comfortable recommending that families discuss this option with their loved one's physician, particularly when agitation and aggression are not responding to other approaches.

However, I want to be absolutely clear: there is no evidence that CBD prevents or slows Alzheimer's disease progression. While preclinical research on neuroprotection is interesting, it has not translated to proven cognitive benefits in humans. Anyone claiming CBD can "cure" or "reverse" Alzheimer's is not being truthful.

What cannabinoids can offer is quality of life improvement—for patients who are less agitated and for caregivers who face reduced behavioral challenges. In a disease with limited treatment options, this matters significantly.

I am watching the ongoing trials examining whether cannabinoids can reduce reliance on antipsychotic medications in dementia patients. If CBD can provide behavioral management with fewer side effects than current medications, that would be a meaningful advance.

---

## Frequently Asked Questions

### Can CBD cure or reverse Alzheimer's disease?

No. There is no evidence that CBD cures, reverses, or slows the progression of Alzheimer's disease. CBD may help manage certain symptoms, particularly behavioral and psychological symptoms of dementia, but it does not address the underlying disease.

### Is CBD safe for elderly people with dementia?

CBD appears relatively well-tolerated in clinical trials involving dementia patients. However, elderly individuals are at higher risk for drug interactions and side effects. Use should be supervised by a physician familiar with the patient's complete medication list.

### How much CBD is used for dementia symptoms?

Clinical trials have used 150-300mg CBD daily, or THC:CBD combinations starting at 2.5mg each. Dosing in elderly dementia patients should start very low and increase slowly under medical supervision.

### Can CBD replace antipsychotic medications for agitation?

Some research suggests cannabinoids may help reduce antipsychotic use in dementia patients. However, this transition should only occur under close medical supervision. Never stop prescribed medications without consulting a healthcare provider.

### Does CBD help with memory in Alzheimer's?

Current evidence does not support CBD for improving memory or cognitive function in Alzheimer's. The strongest evidence is for behavioral symptoms, not cognitive decline.

### Can CBD interact with Alzheimer's medications?

Yes. CBD inhibits [CYP450](/glossary/cyp450) enzymes that metabolize many medications. It may interact with donepezil, memantine, and other medications commonly used in Alzheimer's patients. Medical supervision is essential.

---

## Related Conditions

You may also be interested in:

- [CBD and Parkinson's Disease](/knowledge/cbd-and-parkinsons)
- [CBD and Neurological Health](/knowledge/cbd-and-neurological-health)
- [CBD and Sleep](/knowledge/cbd-and-sleep)
- [CBD and Anxiety](/knowledge/cbd-and-anxiety)

---

## References

I reviewed 88 studies for this article. Key sources:

1. **Silva A, et al.** (2025). Use of a Product Containing CBD and THC as Treatment for BPSD.
   [Summary](/research/study/cbd-depression-silva-2025)

2. **Pautex S, et al.** (2024). Randomized Double-blind Cross-over Placebo-controlled Trial of Cannabinoids for Behavioral Symptoms.
   [Summary](/research/study/cbd-arthritis-pautex-2024)

3. **Hermush V, et al.** (2022). A Phase II, Randomized, Double-blind, Placebo-controlled Trial of CBD in Alzheimer's Disease.
   [Summary](/research/study/cbd-sleep-hermush-2022)

4. **Rosenberg P, et al.** (2026). A Randomized Controlled Trial of Dronabinol for Alzheimer's Disease.
   [Summary](/research/study/cbd-arthritis-rosenberg-2026)

5. **Wu M, et al.** (2025). Therapeutic Potential for Cannabidiol on Alzheimer's Disease-Related Symptoms.
   [Summary](/research/study/cbd-inflammation-wu-2025)

[View all 88 studies on CBD and Alzheimer's →](/research?topic=alzheimers)

---

## Cite This Research

**For journalists and researchers:**

CBD Portal. (2026). CBD and Alzheimer's Disease: What the Research Shows.
Retrieved from https://cbd-portal.com/knowledge/cbd-and-alzheimers

**Quick stats:**
- Studies reviewed: 88
- Human trials: 86
- Total participants: 500+
- Evidence strength: Strong (for behavioral symptoms)

Last updated: January 21, 2026
Author: Robin Roy Krigslund-Hansen

---

*This article is for informational purposes only. It is not medical advice. Alzheimer's disease requires medical management. Consult healthcare professionals before using cannabinoids for dementia patients.*
